National Cancer Institute. SEER Cancer Stat Facts: NHL — Diffuse Large B-Cell Lymphoma (DLBCL) 2024. https://seer.cancer.gov/statfacts/html/dlbcl.html. Accessed 11 September 2024

Medeiros LJ, Chadburn A, Natkunam Y, Naresh KN. WHO 5th edition classification project. Fifth edition of the world health classification of tumors of the hematopoietic and lymphoid tissues: b-cell neoplasms. Mod Pathol. 2024;37(4):100441. https://doi.org/10.1016/j.modpat.2024.100441.

Campo E, Jaffe ES, Cook JR, et al. The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee blood. 2022;140(4):1229-1253. https://doi.org/10.1182/blood.2022015851.

Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–11. https://doi.org/10.1038/35000501.

Article  CAS  PubMed  Google Scholar 

Lenz G, Wright GW, Emre NC, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A. 2008;105(36):13520–5. https://doi.org/10.1073/pnas.0804295105.

Article  PubMed  PubMed Central  Google Scholar 

Shi Y, Xu Y, Shen H, Jin J, Tong H, Xie W. Advances in biology, diagnosis and treatment of DLBCL. Ann Hematol. 2024;103(9):3315–34. https://doi.org/10.1007/s00277-024-05880-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weber T, Schmitz R. Molecular subgroups of diffuse large B cell lymphoma: biology and implications for clinical practice. Curr Oncol Rep. 2022;24:13–21. https://doi.org/10.1007/s11912-021-01155-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–82. https://doi.org/10.1182/blood-2003-05-1545.

Article  CAS  PubMed  Google Scholar 

Read JA, Koff JL, Nastoupil LJ, Williams JN, Cohen JB, Flowers CR. Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithms. Clin Lymphoma Myeloma Leuk. 2014;14(6):460-467.e2. https://doi.org/10.1016/j.clml.2014.05.002.

Article  PubMed  PubMed Central  Google Scholar 

Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–42. https://doi.org/10.1056/NEJMoa011795.

Article  CAS  PubMed  Google Scholar 

Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2005;23(18):4117–26. https://doi.org/10.1200/JCO.2005.09.131.

Article  CAS  PubMed  Google Scholar 

Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2011;2011:498–505. https://doi.org/10.1182/asheducation-2011.1.498.

Article  PubMed  Google Scholar 

Kumar A, Fraz MA, Usman M, et al. Treating diffuse large b cell lymphoma in the very old or frail patients. Curr Treat Options Oncol. 2018;19:50. https://doi.org/10.1007/s11864-018-0565-6.

Article  CAS  PubMed  Google Scholar 

Rask Kragh Jørgensen R, Jakobsen LH, Eloranta S, et al. Effectiveness of R-CHOP versus R-CHOEP for treatment of young patients with high-risk diffuse large B-cell lymphoma: a Danish observational population-based study. Eur J Haematol. 2024;113(5):641–650. https://doi.org/10.1111/ejh.14275.

Wästerlid T, Hartman L, Székely E, Jerkeman M. Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study. Hematol Oncol. 2017;35(2):151–7. https://doi.org/10.1002/hon.2256.

Article  CAS  PubMed  Google Scholar 

García-Suárez J, Bañas H, Arribas I, De Miguel D, Pascual T, Burgaleta C. Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study. Br J Haematol. 2007;136(2):276–85. https://doi.org/10.1111/j.1365-2141.2006.06438.x.

Article  CAS  PubMed  Google Scholar 

Bartlett NL, Wilson WH, Jung SH, et al. Dose-adjusted EPOCH-R compared With R-CHOP as frontline therapy for diffuse large B-Cell lymphoma: clinical outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. J Clin Oncol. 2019;37(21):1790–9. https://doi.org/10.1200/JCO.18.01994.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nowakowski GS, Willenbacher W, Greil R, et al. Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial. Int J Hematol. 2022;115(2):222–32. https://doi.org/10.1007/s12185-021-03241-4.

Article  CAS  PubMed  Google Scholar 

Olszewski AJ, Phillips TJ, Hoffmann MS, et al. Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study. Blood Adv. 2023;7(20):6055–65. https://doi.org/10.1182/bloodadvances.2023010840.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab Vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386(4):351–63. https://doi.org/10.1056/NEJMoa2115304.

Article  CAS  PubMed  Google Scholar 

Maurer MJ, Ghesquières H, Jais JP, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014;32(10):1066–73. https://doi.org/10.1200/JCO.2013.51.5866.

Article  PubMed  PubMed Central  Google Scholar 

International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329(14):987–94. https://doi.org/10.1056/NEJM199309303291402.

Article  Google Scholar 

Kang J, Chae H, Hong JY, et al. Distinct clinical characteristics at diagnosis in patients with late relapses compared with early relapses of diffuse large B-cell lymphoma treated with R-CHOP. Leuk Lymphoma. 2020;6(5):1119–25. https://doi.org/10.1080/10428194.2019.170983124.

Article  Google Scholar 

Munoz J, Deshpande A, Rimsza L, Nowakowski GS, Kurzrock R. Navigating between scylla and charybdis: a roadmap to do better than Pola-RCHP in DLBCL. Cancer Treat Rev. 2024;124:102691. https://doi.org/10.1016/j.ctrv.2024.102691.

Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333(23):1540–5. https://doi.org/10.1056/NEJM199512073332305.

Article  CAS  PubMed  Google Scholar 

Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184–90. https://doi.org/10.1200/JCO.2010.28.1618.

Article  PubMed  PubMed Central  Google Scholar 

Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–8. https://doi.org/10.1182/blood-2017-03-769620.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Allen P. Diffuse large b-cell lymphoma in the elderly: current approaches. Curr Oncol Rep. 2020;22(11):114. https://doi.org/10.1007/s11912-020-00976-x.

Article  CAS  PubMed  Google Scholar 

Coleman M, Ruan G, Elstrom RL, Martin P, Leonard JP. Metronomic therapy for refractory/relapsed lymphoma: the PEP-C low-dose oral combination chemotherapy regimen. Hematology. 2012;17:S90–2. https://doi.org/10.1179/102453312X13336169155970.

Article  CAS  PubMed  Google Scholar 

Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014;32(31):3490–6. https://doi.org/10.1200/JCO.2013.53.9593.

Article  CAS  PubMed  Google Scholar 

van Imhoff GW, McMillan A, Matasar MJ, et al. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: The ORCHARRD Study. J Clin Oncol. 2017;35(5):544–51. https://doi.org/10.1200/JCO.2016.69.0198.

Article  PubMed